Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | LCK | P06239 | 9/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | SCD | O00767 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CASP2 | P42575 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28589359 | 0.85 | DYRK1A (0.74) | LCKRAB9ADYRK1ANPC1CYP1A2 | |
| SCHEMBL544557 | 0.83 | LMNA (0.68) | RAB9ADYRK1ANPC1CYP1A2CYP3A4 | |
| SCHEMBL29506738 | 0.83 | LCK (0.69) | LCKRAB9ADYRK1ANPC1HTT | |
| SCHEMBL17090573 | 0.83 | LCK (0.69) | LCKRAB9ADYRK1ANPC1HTT | |
| SCHEMBL2666847 | 0.83 | DYRK1A (0.67) | LCKRAB9ADYRK1A | |
| SCHEMBL10118217 | 0.81 | RAB9A (0.76) | LCKRAB9ADYRK1ANPC1CYP1A2 | |
| SCHEMBL29809436 | 0.81 | RAB9A (0.76) | LCKRAB9ADYRK1ANPC1CYP1A2 | |
| SCHEMBL3943412 | 0.81 | LCK (0.61) | LCKRAB9ANPC1SMN1; SMN2SCD | |
| SCHEMBL30263005 | 0.81 | LCK (0.61) | LCKRAB9ANPC1SMN1; SMN2SCD | |
| SCHEMBL15839279 | 0.81 | CA2 (0.68) | CA2RAB9ADYRK1ANPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632952-B2 | 4-(2-hydroxy-2-methylpropylamino)benzenesulfonic acid 2-[(piperidine-4-carbonyl)-amino]benzothiazol-6-yl ester; anticancer activity, via modulation of the activity of proteins, in particular of kinases; anticarcinogenic agent | AVENTIS PHARMA S.A. (FR) | 2009-12-15 | — | — | US | disclosed |
| US-20070093488-A1 | Novel Benzothiazoles And The Use Thereof As Medicaments | AVENTIS PHARMA S.A. (FR) | 2007-04-26 | — | — | US | disclosed |
| EP-1745044-A2 | BENZOTHIAZOLE DERIVATIVES HAVING CDK MODULATING ACTIVITY AND USE THEREOF AS ANTICANCER AGENTS | Aventis Pharma S.A. (FR) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005097787-A2 | NOVEL BENZOTHIAZOLES AND THE USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA S.A. (FR) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093488-A1 | Novel Benzothiazoles And The Use Thereof As Medicaments | TFEB, ABAT, BRD4 | CA2 2034/4885LCK 3169/4885RAB9A 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.